NRx Pharmaceuticals wins FDA approval for preservative-free ketamine
NRx Pharmaceuticals has received FDA approval for its Abbreviated New Drug Application (ANDA) for a preservative-free formulation of ketamine, beating the agency's stated 10 November goal date under the Generic Drug User Fee Act. The Wilmington-based company says commercial supply is ready to ship to hospitals and clinics.
The approval is notable in two respects: it removes benzethonium chloride (BZT) from a product that has contained the compound since its original 1970 formulation, and it establishes US domestic manufacturing for a generic sterile injectable that has otherwise been sourced predominantly from overseas.
The preservative question
BZT has been a point of regulatory contention for some years. The FDA has declined to designate it as Generally Recognised as Safe (GRAS) and has banned it from new drugs, consumer hand cleansers, healthcare hand rubs, and intravenous formulations above a defined concentration threshold. NRx filed a Citizen Petition asking the agency to have BZT removed from ketamine altogether, and commissioned a toxicology report arguing that patients receiving ketamine at routine hospital doses may be exposed to BZT levels that exceed the FDA's published maximum daily exposure of one milligram.
Ketamine has appeared on the FDA drug shortage list since 2018, with some manufacturers exiting the market. Jonathan Javitt, chairman and chief executive of NRx, said the company could now label and distribute product immediately. "Ketamine injection has been in short supply since 2018 and currently appears on the FDA drug shortage list," he said. "With manufactured commercial supply on hand, we can now label our product and supply American hospitals and clinics."
The product is manufactured in partnership with Nephron Pharmaceuticals in West Columbia, South Carolina, using blow-fill-seal technology, a high-volume automated process that has largely replaced traditional glass-vial filling for sterile injectables in modern facilities. Blow-fill-seal is widely used in European generic manufacturing and is considered well-suited to reshoring projects because it reduces labour intensity relative to conventional fill-finish lines.
Market context and pipeline
Ketamine's primary use in hospital settings is anaesthesia and pain management, including in labour and delivery, where Javitt noted it is the only intravenous anaesthetic that avoids significant respiratory suppression in the neonate. The generic injectable market is competitive but the active shortage, combined with the regulatory differentiation on BZT, gives NRx a near-term window before other manufacturers can file comparable preservative-free formulations.
Beyond the generic approval, NRx is pursuing a branded intravenous ketamine product, NRX-100, under a New Drug Application with Fast Track Designation for suicidal ideation in depression including bipolar depression. A separate oral candidate, NRX-101 (D-cycloserine and lurasidone combined), holds Breakthrough Therapy Designation for suicidal bipolar depression and received an $11.25 million DARPA contract in October 2026 to fund a Phase 3 trial incorporating robotic transcranial magnetic stimulation.
The ketamine space has attracted growing clinical and commercial attention following the 2019 FDA approval of esketamine nasal spray for treatment-resistant depression. NRx's ANDA approval sits in the generic injectable segment rather than the intranasal or branded CNS market, but the pipeline suggests the company is positioning itself across multiple ketamine-derived opportunities. Investors will watch for pricing and distribution agreements as the immediate commercial milestone, and for Phase 3 data from the NRX-101 DARPA-funded programme as the longer-term value driver.